The bane of non-viral cell and gene therapy

In my previous discussions on the benefits of Nanoplasmid^TM vectors, I touched on eliminating protein and antibiotic markers and the advantage of the RNA-OUT marker system, as well as structured DNA repeats and the plasmid replication challenge. 

Defining paths and building relationships

While research into RNA, including mRNA and related derivatives, has been ongoing for almost 50 years, it’s taken the COVID-19 pandemic to accelerate the development of vaccines using this technology. mRNA provides an incredible opportunity to develop new treatments for viral based, genetically driven, or cancerous diseases.